Elite in Breast Cancer

Dr. Rita K. Nanda

Hematology Oncology | Hematology | Oncology
The University Of Chicago
5841 S Maryland Ave, 
Chicago, IL 
Accepting New Patients
Offers Telehealth
Elite in Breast Cancer
The University Of Chicago
5841 S Maryland Ave, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Rita Nanda is a Hematologist Oncology specialist and a Hematologist in Chicago, Illinois. Dr. Nanda is rated as an Elite provider by MediFind in the treatment of Breast Cancer. Her top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, HER-2 Positive Breast Cancer, and Paget Disease of the Breast. Dr. Nanda is currently accepting new patients.

Her clinical research consists of co-authoring 146 peer reviewed articles and participating in 22 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 128 articles and participated in 22 clinical trials in the study of Breast Cancer.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in IL
Hospital Affiliations
The University Of Chicago Medical Center
Languages Spoken
English
Spanish
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Celtic
  • HMO
  • INSURANCE PLAN
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

THE UNIVERSITY OF CHICAGO
5841 S Maryland Ave, Chicago, IL 60637
Other Locations
THE UNIVERSITY OF CHICAGO
355 E Grand Ave, Chicago, IL 60611

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

22 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase II Open-Label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination With Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer
A Phase II Open-Label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination With Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 24, 2025
Intervention Type: Procedure, Drug, Other
Study Drugs: Atezolizumab, Olaparib
Study Phase: Phase 2
AURORA US: Prospective Biospecimen Repository in Metastatic Breast Cancer
AURORA US: Prospective Biospecimen Repository in Metastatic Breast Cancer
Enrollment Status: Suspended
Publish Date: September 03, 2025
Intervention Type: Procedure, Other
A Randomized, Phase II Study Comparing Trastuzumab and Vinorelbine in Combination With Avelumab or Avelumab and Utomilumab (41BB/CD137 Agonist), in Patients With HER2-positive Metastatic Breast Cancer Who Have Progressed on Prior Trastuzumab and Pertuzumab
A Randomized, Phase II Study Comparing Trastuzumab and Vinorelbine in Combination With Avelumab or Avelumab and Utomilumab (41BB/CD137 Agonist), in Patients With HER2-positive Metastatic Breast Cancer Who Have Progressed on Prior Trastuzumab and Pertuzumab
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2025
Intervention Type: Drug
Study Drugs: Vinorelbine, Trastuzumab, Avelumab, Utomilumab
Study Phase: Phase 2
MARGetuximab Or Trastuzumab (MARGOT): A Phase II Study Comparing Neoadjuvant Paclitaxel/Margetuximab/Pertuzumab to Paclitaxel/Trastuzumab/Pertuzumab in Patients With Stage II-III HER2-positive Breast Cancer
MARGetuximab Or Trastuzumab (MARGOT): A Phase II Study Comparing Neoadjuvant Paclitaxel/Margetuximab/Pertuzumab to Paclitaxel/Trastuzumab/Pertuzumab in Patients With Stage II-III HER2-positive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 26, 2025
Intervention Type: Drug
Study Drugs: Paclitaxel, Pertuzumab, Margetuximab, Trastuzumab
Study Phase: Phase 2
Saci-IO HR+: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in Hormone Receptor-positive (HR+) / HER2- Metastatic Breast Cancer (MBC)
Saci-IO HR+: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in Hormone Receptor-positive (HR+) / HER2- Metastatic Breast Cancer (MBC)
Enrollment Status: Active_not_recruiting
Publish Date: June 25, 2025
Intervention Type: Drug
Study Drugs: Pembrolizumab, Sacituzumab Govitecan
Study Phase: Phase 2
Therapeutic Targeting of ER Beta in Triple Negative Breast Cancer
Therapeutic Targeting of ER Beta in Triple Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2025
Intervention Type: Procedure, Biological
Study Drug: Therapeutic Estradiol
Study Phase: Phase 2
A Randomized, Placebo-Controlled, Double-Blind, Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel (Nab-Paclitaxel, Abraxane®) With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer
A Randomized, Placebo-Controlled, Double-Blind, Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel (Nab-Paclitaxel, Abraxane®) With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 10, 2025
Intervention Type: Drug, Other
Study Drugs: Mifepristone, Nab-Paclitaxel
Study Phase: Phase 2
A Randomized Phase II Study of Pembrolizumab, an Anti-Programmed Cell Death (PD)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
A Randomized Phase II Study of Pembrolizumab, an Anti-Programmed Cell Death (PD)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
Enrollment Status: Completed
Publish Date: May 02, 2025
Intervention Type: Drug, Biological
Study Drugs: Pembrolizumab, Carboplatin, Trastuzumab
Study Phase: Phase 2
A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients With Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded)
A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients With Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded)
Enrollment Status: Active_not_recruiting
Publish Date: March 17, 2025
Intervention Type: Drug
Study Drug: Olaparib
Study Phase: Phase 2
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Enrollment Status: Active_not_recruiting
Publish Date: March 17, 2025
Intervention Type: Drug
Study Drugs: Trastuzumab, Paclitaxel, Trastuzumab emtansine
Study Phase: Phase 2
A Phase 1b/2 Study of the PARP Inhibitor Niraparib in Combination With Trastuzumab in Patients With Metastatic HER2+ Breast Cancer
A Phase 1b/2 Study of the PARP Inhibitor Niraparib in Combination With Trastuzumab in Patients With Metastatic HER2+ Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 04, 2025
Intervention Type: Drug
Study Drugs: Niraparib, Trastuzumab
Study Phase: Phase 1/Phase 2
OXEL: A Pilot Study of Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for Triple Negative Breast Cancer With Residual Disease Following Neoadjuvant Chemotherapy
OXEL: A Pilot Study of Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for Triple Negative Breast Cancer With Residual Disease Following Neoadjuvant Chemotherapy
Enrollment Status: Completed
Publish Date: December 03, 2024
Intervention Type: Drug
Study Drugs: Nivolumab, Capecitabine
Study Phase: Phase 2
ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer: A Phase I/Ib Trial
ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer: A Phase I/Ib Trial
Enrollment Status: Withdrawn
Publish Date: November 18, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With Metastatic Breast Cancer
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: March 07, 2023
Intervention Type: Drug
Study Drugs: Ladiratuzumab vedotin, Trastuzumab
Study Phase: Phase 1
Double Blind, Parallel Groups, Controlled, Randomized Phase II Trial to Evaluate Vaccination With Folate Receptor Alpha Peptide Vaccine With GM-CSF as Vaccine Adjuvant Following Oral Cyclophosphamide Versus GM-CSF/Placebo to Prevent Recurrence in Patients With Triple Negative Breast Cancer
Double Blind, Parallel Groups, Controlled, Randomized Phase II Trial to Evaluate Vaccination With Folate Receptor Alpha Peptide Vaccine With GM-CSF as Vaccine Adjuvant Following Oral Cyclophosphamide Versus GM-CSF/Placebo to Prevent Recurrence in Patients With Triple Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2023
Intervention Type: Drug, Other, Biological
Study Drugs: Cyclophosphamide, Multi-epitope Folate Receptor Alpha Peptide Vaccine, Sargramostim
Study Phase: Phase 2
A Phase Ib/II Trial of Taselisib (GDC-0032), a PI3K Inhibitor, in Combination With Enzalutamide in Patients With Androgen Receptor Positive Triple Negative Metastatic Breast Cancer
A Phase Ib/II Trial of Taselisib (GDC-0032), a PI3K Inhibitor, in Combination With Enzalutamide in Patients With Androgen Receptor Positive Triple Negative Metastatic Breast Cancer
Enrollment Status: Terminated
Publish Date: August 22, 2022
Intervention Type: Drug, Other
Study Drugs: Enzalutamide, Taselisib
Study Phase: Phase 1/Phase 2
An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments
An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments
Enrollment Status: Completed
Publish Date: June 15, 2022
Intervention Type: Drug
Study Phase: Phase 3
Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive Metastatic Breast Cancer Previously Exposed to Inhibitors of the PI3K Pathway: A Phase II Study With Pharmacodynamics Markers
Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive Metastatic Breast Cancer Previously Exposed to Inhibitors of the PI3K Pathway: A Phase II Study With Pharmacodynamics Markers
Enrollment Status: Completed
Publish Date: March 16, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
Enrollment Status: Terminated
Publish Date: July 30, 2021
Intervention Type: Drug
Study Drugs: Tesetaxel and Capecitabine, Capecitabine
Study Phase: Phase 3
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
Enrollment Status: Completed
Publish Date: March 08, 2019
Intervention Type: Drug
Study Phase: Phase 2
Carboplatin, Gemcitabine, and Mifepristone for Advanced Breast Cancer and Recurrent or Persistent Epithelial Ovarian Cancer
Carboplatin, Gemcitabine, and Mifepristone for Advanced Breast Cancer and Recurrent or Persistent Epithelial Ovarian Cancer
Enrollment Status: Completed
Publish Date: September 11, 2018
Intervention Type: Drug, Other
Study Phase: Phase 1
View 21 Less Clinical Trials

145 Total Publications

Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast Cancer.
Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast Cancer.
Journal: medRxiv : the preprint server for health sciences
Published: September 05, 2025
Similar Doctors
Elite in Breast Cancer
Dr. Olufunmilayo I. Olopade
Hematology Oncology | Hematology | Oncology
Elite in Breast Cancer
Dr. Olufunmilayo I. Olopade
Hematology Oncology | Hematology | Oncology

The University Of Chicago Medical Center

5841 S Maryland Ave, 
Chicago, IL 
 (0.1 miles away)
773-702-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Olufunmilayo Olopade is a Hematologist Oncology specialist and a Hematologist in Chicago, Illinois. Dr. Olopade is rated as a Distinguished provider by MediFind in the treatment of Breast Cancer. Her top areas of expertise are Breast Cancer, Ovarian Cancer, Inflammatory Breast Cancer, Salpingo-Oophorectomy, and Hormone Replacement Therapy (HRT). Dr. Olopade is currently accepting new patients.

Elite in Breast Cancer
Dr. Kathy S. Albain
Hematology Oncology | Hematology | Oncology
Elite in Breast Cancer
Dr. Kathy S. Albain
Hematology Oncology | Hematology | Oncology

Loyola University Medical Center

2160 S 1st Ave, 
Maywood, IL 
 (12.9 miles away)
708-216-9000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Kathy Albain is a Hematologist Oncology specialist and a Hematologist in Maywood, Illinois. Dr. Albain is rated as an Elite provider by MediFind in the treatment of Breast Cancer. Her top areas of expertise are Breast Cancer, HER-2 Positive Breast Cancer, Paget Disease of the Breast, and Angiosarcoma. Dr. Albain is currently accepting new patients.

William J. Gradishar
Elite in Breast Cancer
Dr. William J. Gradishar
Oncology
Elite in Breast Cancer
Dr. William J. Gradishar
Oncology
250 E Superior St Ste 4-420, Prentice Women's Hospital, 
Chicago, IL 
 (7.4 miles away)
866-587-4322
Experience:
43+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

William Gradishar is an Oncologist in Chicago, Illinois. Dr. Gradishar has been practicing medicine for over 43 years and is rated as an Elite provider by MediFind in the treatment of Breast Cancer. His top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Paget Disease of the Breast, and Angiosarcoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nanda's expertise for a condition
ConditionClose
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile